+1,720.0%
PWR vs MRNA
+786.4%
+933.7%
-45.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.8% | -2.2% | -2.7% | -4.8% |
| 7D | -7.1% | -12.7% | +5.6% | -6.8% |
| 30D | -7.0% | -20.7% | +13.7% | -6.4% |
| 3M | -15.6% | +46.3% | -61.9% | -16.6% |
| 6M | -21.2% | +305.2% | -326.5% | -27.1% |
| YTD | +32.6% | +561.2% | -528.7% | +18.6% |
| 1Y | +30.2% | +772.1% | -741.9% | +14.5% |
| 3Y | +204.6% | +147.0% | +57.7% | +181.1% |
| 5Y | +365.3% | -26.1% | +391.4% | +338.4% |
| All | +1,720.0% | +786.4% | +933.7% | +1,515.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling